Inactive Instrument

Copytele Inc Stock OTC Bulletin Board

Equities

COPY

US2177211099

Biotechnology & Medical Research

End-of-day quote OTC Bulletin Board
- USD - Intraday chart for Copytele Inc
Sales 2024 * - Sales 2025 * - Capitalization 98.89M
Net income 2024 * -14M Net income 2025 * -15M EV / Sales 2024 * -
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * -
P/E ratio 2024 *
-7.05 x
P/E ratio 2025 *
-6.89 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 95.1%
More Fundamentals * Assessed data

Latest transcript on Copytele Inc

Managers TitleAgeSince
Chief Executive Officer 59 12-10-31
Director of Finance/CFO 57 16-10-31
Corporate Officer/Principal 69 21-09-06
Members of the board TitleAgeSince
Director/Board Member 79 99-06-30
Chief Executive Officer 59 12-10-31
Director/Board Member 63 19-10-22
More insiders
Anixa Biosciences, Inc. is a biotechnology company developing vaccines and therapies that are focused on critical unmet needs in oncology. Its segments include CAR-T Therapeutics, Cancer Vaccines, Anti-Viral Therapeutics and Other. Its vaccine programs include the development of a preventative vaccine against triple negative breast cancer (TNBC), the most lethal form of breast cancer, as well as other forms of breast cancer and the development of a preventative vaccine against ovarian cancer. Its therapeutics programs include the development of a chimeric endocrine receptor T cell therapy, a novel form of chimeric antigen receptor T cell (CAR-T) technology, initially focused on treating ovarian cancer, which is being developed by its subsidiary, Certainty Therapeutics, Inc. (Certainty). Certainty is developing immuno-therapy drugs against cancer. The Company’s vaccine portfolio consists of technology focused on the immunization against specific retired proteins.
More about the company